跳转至内容
Merck
CN

890808P

Avanti

22:0 Trehalose

Avanti Research - A Croda Brand

别名:

D-(+)-trehalose 6,6′-dibehenate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C56H106O13
CAS号:
分子量:
987.43
MDL编号:
UNSPSC代码:
12352211
NACRES:
NA.25

表单

powder

包装

pkg of 1 × 25 mg (890808P-25mg)
pkg of 1 × 5 mg (890808P-5mg)

制造商/商品名称

Avanti Research - A Croda Brand

应用

vaccine development

运输

dry ice

储存温度

−20°C

SMILES字符串

O[C@H]([C@@H](COC(CCCCCCCCCCCCCCCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)COC(CCCCCCCCCCCCCCCCCCCCC)=O)[C@@H]1O)[C@@H]2O)[C@@H]2O

InChI key

ZLJJDBSDZSZVTF-LXOQPCSCSA-N

一般描述

22:0 Trehalose is a bioactive glycolipid and an analog of mycobacterial cord factor.

应用

22:0 Trehalose has been used as an adjuvant for Chlamydia vaccine. It has also been used as a component in adjuvant DMT (dimethyldioctadecylammonium/monophosphoryl lipid A/trehalose 6,6′-dibehenate (DDA/MPL/TDB)) to prepare DMT liposome adjuvanted CTT3H (polyprotein) vaccine.

生化/生理作用

Incorporation of trehalose 6,6′-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets. It acts as an immunomodulator. 22:0 Trehalose is considered less toxic and an efficient vaccine adjuvant for tuberculosis.

包装

5 mL Amber Glass Screw Cap Vial (890808P-25mg)
5 mL Amber Glass Screw Cap Vial (890808P-5mg)

其他说明

For R&D use only. Not for drug, household, or other uses.

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Xindong Teng et al.
Human vaccines & immunotherapeutics, 11(6), 1456-1464 (2015-04-24)
Different strategies have been proposed for the development of protein subunit vaccine candidates for tuberculosis (TB), which shows better safety than other types of candidates and the currently used Bacillus Calmette-Guérin (BCG) vaccine. In order to develop more effective protein

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门